Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-07-28

Tempus AI, Inc.

Tempus sells genomic diagnostics, clinical workflow software, and multimodal data and AI tools to healthcare providers and life sciences customers.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Trusted clinical rails with real mix-shift upside

The core setup is a regulated data-and-diagnostics flywheel: more testing can create more governed data, better tools, and higher-value pharma and workflow revenue. The upside is meaningful, but the company still has to prove that this mix shift can outrun reimbursement friction and integration complexity.

Analysis

Thesis

Tempus can compound faster than a normal diagnostics company if it keeps turning test volume into governed data, workflow embed, and pharma applications revenue; the big win is not raw AI, but owning the trusted clinical rails that AI makes more valuable.

Last Economy Alignment

Tempus owns governed clinical data rights, reimbursed assays, and workflow trust points. Cheaper AI raises the value of those assets more than it commoditizes them, though regulation and generic assistants still pressure the software layer.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.6x (from 5 most recent analyses)

Reasoning

The upside is operational, not magical. Tempus already has real diagnostics scale, real data buyers, and meaningful provider reach; if it converts that into a larger recurring data-and-workflow mix, the market can keep valuing it above a normal lab, but still below pure software.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether Tempus has products; it does. The real risk is whether it can convert a strong clinical-data position into a larger, durable, higher-margin workflow and applications business before reimbursement friction, integration complexity, or valuation discipline pull it back toward a premium-lab multiple.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

The July 20 Personalis deal materially strengthened the recurrence-monitoring path and widened Tempus' oncology stack beyond treatment selection into longitudinal monitoring.
Deal materials disclosed a practical financing gate: Personalis can terminate if Tempus stock is below the $46 lower floor near closing, making market support and execution credibility more important.
The setup into July 30 earnings became more two-sided: the next print is the first hard operating read after the acquisition announcement and before integration work begins.

Forecast update

Lower entry valuation and added oncology breadth modestly improved long-run payoff, partly offset by a tighter financing and integration path.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.65

They control hard-to-copy clinical data rights and sit where tests get ordered and acted on, so cheaper AI can increase demand for what they already own. The risk is that rivals or hospital systems keep the workflow and pricing power, leaving Tempus valued mainly as a testing company.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$66.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research